This latest briefing provides:

• Clinical advice when a patient needs to switch from the selected biosimilar to an alternative product
• Data on the uptake of biosimilars by region (at the end of May 2019)
• An update on the procurement process on the current contract which is due to expire in November 2019
• Information on the ordering process for adalimumab

The briefing also includes information on the citrate content of biosimilars, feedback from patients and clinicians on the patient experience, and reference pricing.

View the update on adalimumab on the Specialist Pharmacy Service website

Previous briefings and resources on adalimumab can viewed here: https://www.sps.nhs.uk/medicines/adalimumab/